Io Biotech, Inc. Financials
This page shows Io Biotech, Inc. (IOBT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Io Biotech, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Io Biotech, Inc. carries a low D/E ratio of 0.00, meaning only $0.00 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 3.33, Io Biotech, Inc. holds $3.33 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 65/100.
Io Biotech, Inc. generates a -203.1% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -64.6% the prior year.
Io Biotech, Inc. passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, Io Biotech, Inc. generates $0.86 in operating cash flow (-$82.3M OCF vs -$95.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Io Biotech, Inc.'s EBITDA was -$94.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 4.0% from the prior year.
Io Biotech, Inc. reported -$95.5M in net income in fiscal year 2025. This represents a decrease of 10.9% from the prior year.
Io Biotech, Inc. earned $-1.45 per diluted share (EPS) in fiscal year 2025. This represents an increase of 26.8% from the prior year.
Cash & Balance Sheet
Io Biotech, Inc. generated -$82.4M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 14.3% from the prior year.
Io Biotech, Inc. held $60.0M in cash against $0 in long-term debt as of fiscal year 2025.
Io Biotech, Inc. had 66M shares outstanding in fiscal year 2025. This represents an increase of 0.0% from the prior year.
Margins & Returns
Io Biotech, Inc.'s ROE was -203.1% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 138.5 percentage points from the prior year.
Capital Allocation
Io Biotech, Inc. invested $71.5M in research and development in fiscal year 2025. This represents an increase of 5.4% from the prior year.
Io Biotech, Inc. invested $44K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 86.4% from the prior year.
IOBT Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $13.7M-17.5% | $16.7M+1.7% | $16.4M | N/A | $20.2M+27.3% | $15.8M+10.7% | $14.3M | N/A |
| SG&A Expenses | $5.6M-13.9% | $6.5M+5.0% | $6.2M | N/A | $6.3M+11.3% | $5.7M-3.4% | $5.9M | N/A |
| Operating Income | -$19.4M+16.5% | -$23.2M-2.6% | -$22.6M | N/A | -$26.5M-23.1% | -$21.5M-6.6% | -$20.2M | N/A |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | -$1.7M-1510.2% | $118K-19.2% | $146K | N/A | $209K-44.1% | $374K-9.9% | $415K | N/A |
| Net Income | -$8.4M+68.0% | -$26.2M-16.9% | -$22.4M | N/A | -$24.0M-16.1% | -$20.7M-6.3% | -$19.5M | N/A |
| EPS (Diluted) | $-0.13+67.5% | $-0.40-17.6% | $-0.34 | N/A | $-0.36-16.1% | $-0.31-3.3% | $-0.30 | N/A |
IOBT Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $40.0M-5.6% | $42.3M-7.5% | $45.7M-32.4% | $67.7M-24.7% | $89.9M-19.3% | $111.5M-13.0% | $128.2M-15.0% | $150.7M |
| Current Assets | $36.8M-5.5% | $39.0M-7.9% | $42.3M-34.8% | $65.0M-24.7% | $86.2M-19.9% | $107.7M-13.3% | $124.1M-15.7% | $147.3M |
| Cash & Equivalents | $30.7M+9.0% | $28.1M-24.1% | $37.1M-38.2% | $60.0M-25.1% | $80.2M-20.4% | $100.7M-14.6% | $118.0M-17.6% | $143.2M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $39.0M-4.1% | $40.7M+110.9% | $19.3M-6.6% | $20.7M+19.0% | $17.4M+14.4% | $15.2M+19.7% | $12.7M-27.7% | $17.6M |
| Current Liabilities | $18.3M-8.0% | $19.9M+8.8% | $18.3M-6.2% | $19.5M+21.4% | $16.1M+17.0% | $13.7M+24.3% | $11.0M-29.7% | $15.7M |
| Long-Term Debt | $16.7M+148.0% | $6.7M | $0 | $0 | N/A | N/A | N/A | N/A |
| Total Equity | $911K-42.8% | $1.6M-94.0% | $26.4M-43.8% | $47.0M-35.2% | $72.6M-24.6% | $96.3M-16.6% | $115.5M-13.3% | $133.2M |
| Retained Earnings | -$416.3M-2.1% | -$408.0M-6.9% | -$381.7M-6.2% | -$359.3M-9.6% | -$328.0M-7.9% | -$304.0M-7.3% | -$283.3M-7.4% | -$263.8M |
IOBT Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$18.5M+6.8% | -$19.8M+14.1% | -$23.1M-17.6% | -$19.6M+5.7% | -$20.8M-22.5% | -$17.0M+31.9% | -$24.9M-9.4% | -$22.8M |
| Capital Expenditures | $4K-84.6% | $26K-7.1% | $28K+154.5% | $11K+10.0% | $10K-16.7% | $12K+9.1% | $11K-90.2% | $112K |
| Free Cash Flow | -$18.5M+6.9% | -$19.8M+14.1% | -$23.1M-17.6% | -$19.6M+5.7% | -$20.8M-22.5% | -$17.0M+31.9% | -$24.9M-8.9% | -$22.9M |
| Investing Cash Flow | -$4K+84.6% | -$26K+7.1% | -$28K-154.5% | -$11K-10.0% | -$10K+16.7% | -$12K-9.1% | -$11K+90.2% | -$112K |
| Financing Cash Flow | $21.3M+85.2% | $11.5M | $0 | N/A | $0 | $0 | $0+100.0% | -$10K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
IOBT Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | -919.7%+727.1pp | -1646.8%-1561.9pp | -84.9% | N/A | -33.1%-11.6pp | -21.5%-4.6pp | -16.9% | N/A |
| Return on Assets | -21.0%+41.0pp | -61.9%-12.9pp | -49.0% | N/A | -26.7%-8.1pp | -18.6%-3.4pp | -15.2% | N/A |
| Current Ratio | 2.01+0.1 | 1.96-0.4 | 2.32-1.0 | 3.33-2.0 | 5.37-2.5 | 7.84-3.4 | 11.24+1.9 | 9.37 |
| Debt-to-Equity | 18.29+14.1 | 4.22+4.2 | 0.000.0 | 0.00-0.2 | 0.24+0.1 | 0.16+0.0 | 0.11-0.0 | 0.13 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Io Biotech, Inc. profitable?
No, Io Biotech, Inc. (IOBT) reported a net income of -$95.5M in fiscal year 2025.
What is Io Biotech, Inc.'s EBITDA?
Io Biotech, Inc. (IOBT) had EBITDA of -$94.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Io Biotech, Inc. have?
As of fiscal year 2025, Io Biotech, Inc. (IOBT) had $60.0M in cash and equivalents against $0 in long-term debt.
What is Io Biotech, Inc.'s return on equity (ROE)?
Io Biotech, Inc. (IOBT) has a return on equity of -203.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Io Biotech, Inc.'s free cash flow?
Io Biotech, Inc. (IOBT) generated -$82.4M in free cash flow during fiscal year 2025. This represents a -14.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Io Biotech, Inc.'s operating cash flow?
Io Biotech, Inc. (IOBT) generated -$82.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Io Biotech, Inc.'s total assets?
Io Biotech, Inc. (IOBT) had $67.7M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Io Biotech, Inc.'s capital expenditures?
Io Biotech, Inc. (IOBT) invested $44K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Io Biotech, Inc. spend on research and development?
Io Biotech, Inc. (IOBT) invested $71.5M in research and development during fiscal year 2025.
What is Io Biotech, Inc.'s current ratio?
Io Biotech, Inc. (IOBT) had a current ratio of 3.33 as of fiscal year 2025, which is generally considered healthy.
What is Io Biotech, Inc.'s debt-to-equity ratio?
Io Biotech, Inc. (IOBT) had a debt-to-equity ratio of 0.00 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Io Biotech, Inc.'s return on assets (ROA)?
Io Biotech, Inc. (IOBT) had a return on assets of -141.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Io Biotech, Inc.'s cash runway?
Based on fiscal year 2025 data, Io Biotech, Inc. (IOBT) had $60.0M in cash against an annual operating cash burn of $82.3M. This gives an estimated cash runway of approximately 9 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Io Biotech, Inc.'s Piotroski F-Score?
Io Biotech, Inc. (IOBT) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Io Biotech, Inc.'s earnings high quality?
Io Biotech, Inc. (IOBT) has an earnings quality ratio of 0.86x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Io Biotech, Inc.?
Io Biotech, Inc. (IOBT) scores 27 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.